Research on adults who take S.S.R.I.s shows they tamp down sexual desire. Why aren’t we studying what that could mean for ...
Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsRick Winningham - CEO & DirectorRhonda Farnum ...
Most patients with sickle cell disease who go to the ED for vaso-occlusive crises do not get triaged according to guideline ...
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...
Papcemias FDA Approval -- Granted full FDA approval in August with the first and only available treatment for all adults with recurrent respiratory papillomatosis (RRP); label is broad with no ...
Precigen, Inc. ( PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good afternoon, ladies and gentlemen, and welcome to the Precigen Third Quarter 2025 Financial Results and Business Update ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) ...
Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...
RWJBarnabas Health and SciTech Scity launch a pilot using Biobeat’s FDA-cleared cuffless blood pressure patch at Jersey City ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 Earnings Call Transcript November 12, 2025 Acumen Pharmaceuticals, Inc.
Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings, and welcome to the Pelthos Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please ...
Texas voters approved a generational investment into water infrastructure Tuesday night after approving an additional $20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback